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Abstract. In this study, the electrochemical reduction and determination of oxcarbazepine were easily  
realized in various buffer solutions in the pH range of 4.50 to 11.15 in real samples using glassy carbon 
electrode (GCE) by cyclic voltammetric (CV) and differential pulse voltammetric (DPV) techniques. The 
influence of pH on the cathodic peak current and peak potential was investigated. Scan rate studies were 
also completed. The diffusion controlled nature of the peak was established. The best results for the quan-
titative determination of oxcarbazepine were obtained by DPV technique in Britton-Robinson (BR) buffer 
(pH 8.05). In this basic medium, one irreversible and sharp cathodic peak was observed. A linear  
calibration curve for DPV analysis was constructed in the oxcarbazepine concentration range of 8×10–6 to 
1×10–4 M. Limit of detection (LOD) and limit of quantification (LOQ) were obtained as 1.65×10–6 and 
5.51×10–6 M, respectively. Repeatability, reproducibility, precision and accuracy of the developed  
technique were checked in spiked human urine and tablet dosage forms by recovery studies and results of 
the high performance liquid chromatography (HPLC) technique. A reduction mechanism for the electrode 
reaction was proposed.  
Keywords: oxcarbazepine, human urine, dosage form, electrochemical reduction, determination, high  
performance liquid chromatography (HPLC) 
 
INTRODUCTION 
Oxcarbazepine is an anticonvulsant and mood  
stabilizing drug, used primarily in the treatment of epi-
lepsy (Scheme 1). It is also used to treat anxiety and 
mood disorders, and benign motor tics. The drug is 
administered both orally and intravenously.1,2 
Oxcarbazepine was determined in pharmaceutical 
dosage forms and biological samples by chromatog-
raphy1–7 and spectrophotometry8 techniques. However, 
these techniques are time consuming and have high 
cost. 
So far, only a few papers have been published on 
the electroanalytical determination of oxcarbazepine 
based on its reduction behavior.1,2 However, the deter-
mination of oxcarbazepine on glassy carbon electrode 
(GCE) based on its detailed electrochemical reduction 
behavior and determination in real samples has not been 
reported to date. In this study, reduction and the  
determination of oxcarbazepine was realized in spiked 
human urine and tablet dosage forms. 
The CV technique is one of the most advanced 
and most sensitive electroanalytical techniques. It  
combines the advantages of the pulse voltammetric 
techniques capable of discriminating against the capaci-
tive current and the cyclic voltammetry techniques that 
provide an insight into the mechanism of the electrode 
reaction. In addition, this technique is particularly well 
suited for quantitative determination of the redox cou-
ples immobilized on the electrode surface.9–12 Another 
important advantage of these proposed techniques over 
other techniques is that they can be applied directly  
to the analysis of pharmaceutical dosage forms and 
 
Scheme 1. Chemical structure of oxcarbazepine. 
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biological samples without the need for extensive sam-
ple preparation, since there is no interference from the 
excipients and endogenous substances.12 
There are two main objectives of this study. The 
first is to investigate the detailed electro-reduction  
behavior of oxcarbazepine based on its electroactive 
groups at GCE by CV and DPV techniques. The second 
is to develop new voltammetric techniques for fully 
validated, simple, selective, sensitive, rapid and low 
cost procedures for quantitative determination of 
oxcarbazepine in biological samples and pharmaceutical 
dosage forms without any time-consuming extraction or 
evaporation steps prior to drug assay. The proposed 
voltammetric techniques are more rapid and simpler 




A Model Metrohm 757 VA Trace Analyzer (Herisau, 
Switzerland) was used for the voltammetric measure-
ments, with a three-electrode system consisting of  
glassy carbon working electrodes (GCE;  = 3 mm, 
Metrohm), a platinum wire auxiliary electrode and a  
Ag / AgCl (KCl 3 M, Metrohm) reference electrode. 
Before each measurement the glassy carbon working 
electrode was polished manually with polishing alumina 
(prepared from  = 0.01m aluminum oxide) on an 
alumina polish pad then rinsed with ultra pure deionized 
water and ethanol. Oxygen was removed from the sup-
porting electrolyte solution by the passage of argon gas 
(analytically pure 99.99 %) for 5 min before all  
measurements. Furthermore, the argon gas was also 
passed through each sample solution for 60 s before 
each measurement. In each new experiment, a new bare 
electrode surface was used. 
All pH measurements were made with a Model 
Metrohm 744 pH meter (Herisau, Switzerland. All  
measurements were carried out at the temperature of the 
laboratory (15–20 °C). For the analytical application, 
the following parameters were employed: pulse  
amplitude 50 mV; pulse time 0.04 s, voltage step  
0.009 V, voltage step time 0.2, scan rate in the range 
10–1000 mVs–1 (CV). 
An Agilent 1100 model high performance liquid 
chromatography (HPLC) apparatus was used for the 
HPLC measurements, with an electrochemical detector. 
 
Drug and Chemicals 
For this study oxcarbazepine and its oxilepsi® tablet 
dosage forms were kindly supplied by Eczacıbası  
(Istanbul, Turkey). A stock solution of 1.0×10–2 M  
was prepared by dissolving an accurate mass of the  
drug in an appropriate volume of ethanol kept in the  
refrigerator. The working solutions for the voltammetric 
investigations were prepared by dilution of the stock 
solution with ethanol. All solutions were protected  
from light and were used within 24 h to avoid decompo-
sition. The 0.067 M phosphate buffer, pH 4.50–7.50 
(sodium hydrogen phosphate, Na2HPO4, Riedel, Seelze, 
Germany and sodium dihydrogen phosphate, NaH2PO4, 
Riedel, Seelze, Germany), 0.2 M acetate buffer, pH 
3.51–5.51 and 0.04 M Britton Robinson buffer, pH 
2.09–12.00 (acetic acid, Riedel, Seelze, Germany,  
100 m / m % + boric acid, Merck, Darmstadt, Germany + 
phosphoric acid, Carlo Erba, Rodeno, France,  
85 m / m %) were used for the supporting electrolyte 
solutions. DI water with 18.2 M cm–1 conductivity 
(Sartorius Arium model Water Systems) was used 
throughout the experiments. Other chemicals, all of 
analytical-reagent grade, (Merck) were used. Oxilepsi® 
tablets (Eczacıbası, Inc, Istanbul, Turkey) were labeled 
to contain 300 mg oxcarbazepine per tablet. 
For the HPLC experiments, methanol (HPLC  
gradient, J. T. Baker, 8402), phosphoric acid (Riedel-de 
Haen, 30417) and bi-distilled water were used. 
 
Calibration Graph for Quantitative Determination  
Oxcarbazepine was dissolved in ethanol to obtain  
1×10–2 M stock solution. This solution was diluted with 
ethanol to obtain diluted oxcarbazepine concentrations. 
For optimum conditions described in the experimental 
section, a linear calibration curve for DPV analysis was 
constructed in the oxcarbazepine concentration range 
8×10–6–1×10–4 M for working electrode. The repeatabil-
ity, accuracy and precision were checked. 
 
Working Voltammetric Procedure of Spiked Tablet 
Dosage Forms 
Ten tablets were weighed and ground to a fine powder 
and 1×10–2 M drug solution was prepared with ethanol. 
To eliminate interfering excipients other than pure drug, 
the contents of the tube were centrifuged to insoluble 
species left to precipitate for 20 min at 4000 rpm to 
affect complete dissolution and then diluted to volume 
with the same solvent. Appropriate solutions were pre-
pared by taking suitable aliquots of the clear supernatant 
liquor and diluting with selected supporting electrolyte 
solution. Each solution was transferred into the 
voltammetric cell and de-aerated with argon (analytical-
ly pure, 99.99 %) for 5 min before measurement. 
 
Working Voltammetric Procedure of Spiked Human 
Urine  
Urine obtained daily from a volunteer was diluted to the 
ratio 1 : 9 with ethanol. Firstly, 9.4 mL 0.04 M BR (pH 
8.02) was put into the voltammetric cell and its 
voltammogram was recorded as a blank. Then 600 µL 
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of the diluted urine solution was added to this solution 
and its voltammogram was recorded as an urine blank. 
After that 40 µL urine sample (1×10–2 M oxcarbazepine 
solution in urine) was added to the same solution, its 
voltammogram was recorded. Then 20 µL of 1×10–2 M 
oxcarbazepine solution was added three times and their 
voltammograms were recorded after every addition. 
 
RESULTS AND DISCUSSION 
Electrochemical Reduction Behavior of 
Oxcarbazepine  
There is no detailed electrochemical study in which the 
reduction process of oxcarbazepine and its determina-
tion at GCE has been studied so far. Therefore, the elec-
trochemical reduction process and the determination 
using this electrode were firstly carried out by CV and 
DPV techniques. CV measurements performed with 
oxcarbazepine solution of 1×10–4 M at GCE in different 
buffers are given in Figure 1a–d. 
The reduction peak of oxcarbazepine appeared in 
0.04 M Britton-Robinson (BR) buffer, pH 8.05–10.04 
(Fig. 1a, b) and 0.067 M phosphate buffer, pH 4.50–
7.50 (Fig. 1d), while the peak disappeared in 0.2 M 
acetate buffer, pH 3.51–5.51 (Figure 1c). 
The effects of various potential scan rates between 
10–1000 mVs–1 on the peak potential and the peak  
current of 1×10–4 M oxcarbazepine (pH 8.05) were 
evaluated (Figure 2). 
A negative shift in the peak potential confirmed 
the reversibility of the reduction process.20–21 Potential 
scan rate studies were then performed to assess whether 
the processes on GCE were under diffusion- or adsorp-
tion-control.9–23 We employed two tests for this proce-
dure. The relationship existing between peak current 
and scan rate between 10–1000 mVs–1 are as follows: 
1/2 1





   
1
plog( /μA) 0.4846log( / mV s ) 1.1313,    





From both equations, correlation coefficient and 
slope were 0.995 and 0.4846 respectively. These values  
indicate that the electrode reaction was diffusion-
controlled.9–20 Therefore, a diffusion component must 
be taken into account. Other studies were conducted in 
line with this phenomenon. 
Next, in order to obtain the optimum experimental 
conditions for the analytical application, the influence of 
pH on peak current and peak potential in the range of 
pH 4.50–11.15 were studied in different buffers at GCE 
by CV and DPV techniques. All the graphics obtained 
from CV and DPV were found to be similar. For this 
reason, only DPV results are given as I vs. pH and E vs. 
pH plots in Figure 3a and Figure 3b for GCE. 
The peak current (ip) versus pH plot shows that the 
peak current was maximum and the shape of curve was 
better in 0.04 M BR (pH 8.05) buffer (Figure 3a). For 
this reason, 0.04 M BR buffer (pH 8.05) was chosen due 
to the sharp response and better peak shape for the cali-
bration of pharmaceutical dosage form and urine sam-
ples.20,21 The voltammetric response was strongly pH 
dependent. The ip changed in the range of pH 5.0–10.0. 
Ip increased with pH from about 5.0 to 10.0, while it 
decreased after about pH 10.0. No peak appeared below 
pH 5.0 (Figure 1c) and above 10.0. The cathodic peak 
potential slightly shifted to less negative values with 
increasing pH (Figure 3b). These can also be explained 
by changes in protonation of the acid-base functions in 
the oxcarbazepine molecules (Scheme 2).20,21 
 
Figure 1. Selected cyclic voltammograms of 1×10–4 M
oxcarbazepine in (a) 0.04 M BR (pH 8.05); (b) 0.04 M BR
(pH 10.04); (c) 0.2 M acetate (pH 4.76); and (d) 0.067 M
phosphate (pH 7.39) buffers on GCE. Scan rate: 100 mVs–1. 
Figure 2. Cyclic voltammograms of 1×10–4 M oxcarbazepine
in chosen 0.04 M Britton-Robinson (BR) buffer (pH 8.05)
at GCE. Scan rates: (a) 50; (b) 100; (c) 250; ; (d) 600; and
(e) 1000 mVs–1. 
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Reduction Mechanism of the Electrode Reaction  
When describing electrochemical reactions, an "E" and 
"C" formalism is often employed.19 The E represents an 
electron transfer; sometimes EO and ER are used to  
represent oxidations and reductions respectively. The C 
represents a chemical reaction which can be any  
elementary reaction step and is often called a "follow-
ing" reaction. 
As can be seen from the reduction mechanism, in 
the first stage there is a negative attack of the electron to 
positive carbon atom. The negative charge of the  
electron on the electrode affects the carbon atom and 
carbon radical forms. Then one electron of carbon in the 
carbon-oxygen bonds is repelled entirely onto the oxy-
gen, giving it a negative charge. The negative oxygen 
ion takes a hydrogen ion from a water molecule or the 
acid in the solution in the second stage of the reaction. 
In the third step, this radical carbon atom takes one 
more electron and carbonium occurs. In the last step, 
carbonium takes a H+ ion from the solution with the 
reaction C and then alcohol forms.19 
 
Validation Parameters for the Quantitative Analysis 
On the basis of the electrochemical reduction of 
oxcarbazepine, DPV techniques were used to develop 
the quantitative determination of the pure active materi-
al in spiked human urine and drug. The optimum exper-
imental conditions were chosen from studies of the 
variation of the peak current on pulse amplitude and 
potential step. Using the optimum conditions described 
in the experimental section, the voltammograms for 
various concentrations of oxcarbazepine were recorded 
in 0.04 M BR buffer (pH 8.05) on GCE by applied DPV 
technique (Figure 4). 
Quantitative evaluation based on the linear  
correlation between the reduction peak current and 
concentration was carried out. As a result of this, good 
correlations were obtained for oxcarbazepine in the 
concentration range of 8×10−6 to 1×10−4 M on GCE. 
Related equations for the plot of the logarithm of  
the reduction peak current versus the logarithm of  
the regression parameters of the calibration curve  
obtained from ten DPV measurements are given in  
Table 1. 
Validation of the procedure for the quantitative  
determination of the oxcarbazepine was examined via 
evaluation of the limit of detection (LOD), limit of 
quantification (LOQ), precision: repeatability (intraday), 
reproducibility (interday) and accuracy by DPV  
technique (Table 1) 9−24. 
Scheme 2. The possible mechanism of the electrochemical reduction of oxcarbazepine. 
 
Figure 3. Effect of pH on 5×10–5 M oxcarbazepine DPV
(a) peak current; and (b) peak potential; (□) phosphate
(0.067 M) and (◊) Britton-Robinson buffers (0.04 M). 
 
Figure 4. The calibration voltammograms at different concen-
trations (b−h) of oxcarbazepine at GCE by DPV; (a) support-
ing electrolyte (0.04 M BR buffer, pH 8.05); (b) 8.0×10−6;
 (c) 1.0×10−5; (d) 3.0×10−5; (e) 5.0×10−5; (f) 7.0×10−5;
(g) 9.0×10−5; and (h) 1.0×10−4 mol dm−3 oxcarbazepine. 
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LOD and LOQ were calculated on the electro-
reduction peak current using the following equations: 
LOD = 3 s / m, LOQ = 10 s / m (s is the standard devia-
tion of the peak current over five runs, m is the slope of 
the calibration curve).9−24 The achieved LOD and LOQ 
were 1.65×10−6 and 5.51×10−6 M for GCE respectively. 
The repeatability and reproducibility of the current 
measurement were calculated by DPV technique from 
ten independent runs as 2.43 and 0.41 % R.S.D. respec-
tively for 5×10−5 M oxcarbazepine on GCE. The repeat-
ability and reproducibility of the peak potential meas-
urement were also calculated by DPV technique from 
ten independent runs as 1.85 and 0.51 % R.S.D. respec-
tively for 5×10−5 M oxcarbazepine on GCE. 
 
Pharmaceutical Applications  
The amount of oxcarbazepine in commercial tablets was 
calculated by reference to the appropriate calibration 
plots (Table 2). 
As can be seen from Table 2, the proposed tech-
niques could be successfully applied to oxcarbazepine 
assay in tablets without any interference. As far as we 
are aware there is no official technique in the pharma-
copoeias or other literature describing the determination 
of oxcarbazepine in human urine and pharmaceutical 
dosage forms. For this reason, the proposed techniques 
were checked by performing recovery tests. To deter-
mine whether excipients in the tablets interfered with 
the analysis, the accuracy of the proposed methods were 
evaluated by recovery tests after the addition of a cer-
tain amount of pure drug to pre-analyzed formulations 
of oxcarbazepine (Table 3).  
DPV voltammograms of oxcarbazepine in spiked 
urine samples are given in Figure 5.  
As can be seen in Figure 5, no extra reduction 
peak and noise peaks appeared in the biological matrix 
(human urine). The recovery studies were also carried 
out in human urine (Table 3). 
The results showed the validity of the proposed 
techniques for the quantitative determination of 
oxcarbazepine in human urine and tablets. The proposed 
DPV technique proved to be sufficiently precise and 
Table 1. Quantitative analysis parameters of oxcarbazepine 
obtained from calibration plots in BR solution (pH 8.05) at 
GCE by DPV technique 
Parameters Results
Measured potential, E / V −1.32
Linear concentration range / M 8×10−6−1×10−4
Slope / mA M 1.67×104
±S.D. of slope 0.042
Intercept / nA 0.06
±S.D. of intercept 0.013
Correlation coefficient, r 0.999
Number of measurements, n 5
LOD / M 1.65×10−6
LOQ/ M 5.51×10−6
R.S.D of repeatability of peak current 
(intraday) / % 
2.43(a)
R.S.D of reproducibility of peak  
current (interday)/ % 
1.51(a)
R.S.D of repeatability of peak 
potential (intraday) / % 
1.85(a)
R.S.D of reproducibility of peak  
potential (interday) / % 
0.51(a)
(a) Concentration: 5×10−5 M. 
 
Table 2. The assay of found oxcarbazepine in commercial 
oxilepsi® and mean recoveries of spiked oxcarbazepine in 
oxilepsi drug tablets on GCE by DPV technique 
Labeled claim of oxcarbazepine in oxilepsi 
drug /mg 
300
Amount of oxcarbazepine found / mg 314.90
R.S.D. of amount found / % 1.29
Bias / % 4.96
Spiked oxcarbazepine to oxilepsi drug / mg 50.00
Found spiked oxcarbazepine / mg 48.79
Recovery of found oxcarbazepine / % 97.6
R.S.D. of recovery / % 1.47
Bias / % 2.40
 
 
Figure 5. Differential pulse voltammograms of oxcarbazepine
in spiked urine samples (a) supporting electrolyte (0.04 M BR,
pH 8.05); (b) 9.4 mL a + 0.6 µL diluted urine (1 mL urine +
9 mL ethanol); (c) 4×10−5 oxcarbazepine with urine;
(d) 2×10−-5; (e) 4×10−5; and (f) 6×10−5 M oxcarbazepine. 
Table 3. The recovery amount of oxcarbazepine in spiked 
human urine on GCE by DPV technique 
Medium Human urine
Oxcarbazepine added / M 4×10−5
Oxcarbazepine found / M 4.01×10−5
Number of measurements, n 5
Average recovery / % 100.25
R.S.D. / % 0.42
Bias / % 0.25
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accurate for reliable electro analytical analysis of 
oxcarbazepine. 
 
Chromatographic Studies  
Chromatographic techniques are a good alternative to 
the proposed voltammetric techniques for drug analysis. 
Optimization of the chromatographic resolution of 
ionogenic compounds by chromatographic techniques 
has been actively researched. Due to the specific ioniza-
tion characteristics of this solute, the two most useful 
optimization parameters are the pH and organic modifi-
er content of the mobile phase. For ionizable com-
pounds, since changes in solvent content of the mobile 
phase affect the retention behavior, optimization of this 
compound is often carried out at fixed pH.25 This study 
focuses mainly on the organic modifier effect of the 
mobile phase on the chromatographic behavior of 
oxcarbazepine. 
The HPLC system is an Agilent 1100 series  
(Agilent Technologies, USA), including a quaternary 
solvent delivery pump, a thermostat column compart-
ment with HP 1049 A - programmable electrochemical 
detector (ECD) and a manual sample injection valve 
with a 20 µL loop. Chromatographic separation was 
carried out using a Zorbax Eclipse XDB-C8 (150 mm × 
4.6 mm i.d., 5µm) column. Methanol (HPLC gradient, 
J.T. Baker 8402), o-phosphoric acid (Redel-de Haen 
30417) and bi-distilled water were used for the mobile 
phase. Distilled water was used after being filtered 
through 0.22 µm pore diameter Millipore Express- 
PVDF vacuum filter unit. 
Good correlations were obtained for oxcarbaze-
pine in the concentration range of 7.7×10−6–7.7×10−4 M 
using the HPLC tehnique. Some validation parameters 
for the quantitative determination of the oxcarbazepine 
were examined via evaluation of the limit of detection 
(LOD) and limit of quantification (LOQ) (Table 4). 
LOD and LOQ were calculated using the follow-
ing equations: LOD = 3 s / m, LOQ = 10 s / m. The 
achieved LOD and LOQ were 4.70×10−6 and  
6.71×10−6 M for GCE respectively. The results of 
voltammetric analysis were compared with the high 
performance liquid chromatography (HPLC) technique 
(Table 4). 
As shown in Table 4, voltammetry results were 
identical to the HPLC results. This indicates the accura-
cy of proposed voltammetry technique. 
 
CONCLUSION 
As far as we know, in this work, the determination of 
oxcarbazepine in human urine and in tablet form based 
on its electrochemical reduction on GCE was studied by 
voltammetric techniques for the first time. Good recov-
eries (97.6 %) indicated excipients do not interfere with 
the analysis. 
The principal advantage of these proposed tech-
niques over other techniques is that they may be applied 
directly to the analysis of pharmaceutical dosage forms 
and to biological samples without the need for extensive 
sample preparation, since there was no interference 
from excipients or endogenous substances. Another 
advantage is that the developed techniques are rapid, 
requiring about 5 min to run any sample and involves no 
sample preparation other than dissolving, diluting, pre-
cipitating, centrifuging and transferring an aliquot to the 
supporting electrolyte. This paper is not intended to be a 
study of the pharmacodynamic properties of oxcarbaze-
pine because only healthy volunteers were used for 
sample collection and results might be of no signifi-
cance. It only indicates the possibility of monitoring this 
compound which makes the technique useful for phar-
macokinetic and pharmacodynamic purposes.9−18,21 In 
addition to all of the above, the proposed techniques 
might be a rapid and simple alternative to more compli-
cated chromatographic (HPLC) or spectrometric (UV) 
techniques for routine analysis of oxcarbazepine in any 
medium where considerably little interference takes 
place. 
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